Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults

Respiratory Syncytial Virus Infections Clinical Trial

Official title:

A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of BLB-201 Vaccine in Healthy Young Adults and Older Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05281263
• Other study ID #: BLB-201-001
• Status: Completed
• Phase: Phase 1
• Start date: July 20, 2022
• Est. completion date: May 3, 2023

Study information

• Verified date: December 2023
• Source: Blue Lake Biotechnology Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 1 trial is an open-label trial to evaluate the safety, tolerability and immunogenicity of a single dose (10^7.5 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered as a single dose in 15 healthy young adults ages 18-59 years, and 15 older adults ages 60-75 years.

Description:

This will be an open-label, age-escalation phase 1 trial of the PIV5 virus-vectored BLB-201 vaccine in healthy adults (males and nonpregnant females) 18 to 59 years of age (Group 1), and 60 to 75 years of age (Group 2). The trial is designed to assess the safety, tolerability, and immunogenicity of a single dose of intranasal BLB-201 at 10^7.5 plaque- forming units (PFU) in both Group 1 and Group 2. The first 4 subjects in each group will be enrolled as sentinels and vaccination will proceed in a staged fashion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: May 3, 2023
• Est. primary completion date: December 5, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Provide informed consent prior to initiation of any trial procedures.

• Be able to understand and agrees to comply with planned trial procedures and be available for all trial visits and phone calls.

• Healthy male or non-pregnant female, between 18 and 59 years of age (Group 1) or between60 and 75 years of age (Group 2), inclusive, at time of trial vaccination.

• Women of childbearing potential must agree to use or have practiced true abstinence or use at least one acceptable primary form of contraception. Note: These criteria are applicable to females in a heterosexual relationship and child-bearing potential (i.e., the criteria do not apply to subjects in a same sex relationship).

• Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to each vaccination.

• Male subjects of childbearing potential* must use condoms to ensure effective contraception with a female partner of childbearing potential from vaccination until 90 days after vaccination. Such female partners must also use an acceptable form of primary contraception as described under inclusion criterion #4. If barrier methods are to be used, then double barrier methods of protection are required, i.e. male condom, in combination with a cap, diaphragm, or sponge with spermicide. *Biological males who are post-pubertal and considered fertile until permanently sterile by bilateral orchiectomy or vasectomy.

• Male subjects agree to refrain from sperm donation from the time of vaccination until 90 days after vaccination.

• Female subjects agree to refrain from egg donation from time of vaccination until 90 days after vaccination.

• In good health.

Exclusion Criteria:

• History of clinically-significant or major disease that may interfere with a subject completing the trial and necessary investigations.

• Have an acute illness as determined by the site PI or sub-investigator within 72 hours prior to trial vaccination.

• Women who are pregnant, lactating, or unwilling to take effective measures to prevent pregnancy for at least 3 months after vaccination.

• Receipt of any live vaccine within the 30 days prior to trial vaccination.

• Receipt of any inactivated vaccine within the 14 days prior to trial vaccination.

• Receipt of any investigational vaccine within 12 months prior to trial vaccination (not including vaccines made available under an FDA emergency-use authorization).

• Any prior receipt of any investigational RSV vaccine or any PIV5-based vaccine (e.g. CVXGA1).

• Intention to receive any other vaccination before the last in person scheduled visit of the trial.

• Receipt or anticipated receipt of immunoglobulin or blood products within 90 days prior to trial vaccination through trial period.

• Loss (including blood donations) of 470 mL or more of blood within 90 days prior to trial vaccination.

• Receipt or anticipated receipt of systemic glucocorticoids within 30 days prior to trial vaccination through trial period.

• Receipt or anticipated receipt of any antiviral drug within 7 days prior to vaccination through 14 days after trial vaccination.

• History and/or symptoms indicative of upper or lower respiratory tract infection within 14 days prior to initial trial vaccination (e.g. cough, sore throat, body temperature of 99.5°F or greater, nasal congestion, dyspnea, tachypnea, wheezing, fatigue, myalgia).

• Any clinically significant history of heavy nosebleeds.

• History of chronic sinus infection.

• Neurological and neurodevelopmental conditions (e.g., cerebral palsy, epilepsy, stroke, seizures).

• History of postinfectious or postvaccine neurological sequelae.

• Autoimmune, inflammatory, vasculitic, or rheumatic disease or immunodeficiency disorder.

• Any significant abnormality altering the anatomy of the nose.

• History of significant/severe wheeze, respiratory symptoms resulting in hospitalization, or known bronchial hyperreactivity to viruses.

• History of asthma or reactive airway disease as an adult, cystic fibrosis, bronchopulmonary dysplasia, or chronic obstructive pulmonary disease.

• History of anaphylaxis or other severe allergic reaction, e.g., generalized urticaria, angioedema, or other significant reaction to any previous licensed or unlicensed vaccines. - Have a diagnosis of schizophrenia, bipolar disease, or other psychiatric disease that may interfere with subject compliance or safety evaluations.

• Use or anticipated use during the conduct of the trial of high-dose inhaled corticosteroids from 30 days prior to 14 days after trial vaccination.

• Receipt or anticipated receipt of, within 7 days prior to through 28 days after trial vaccination, any intranasal medication including FDA-approved prescription or over-the-counter products or non-FDA-approved alternative medicine products (e.g. Ayurvedic oil or other naturopathic substances).

• Currently smoking or vaping, or history of regular smoking or vaping in the past two years.

• Anticipated use of nasal irrigation (e.g. Neti Pot™) after enrollment through 28 days after trial vaccination.

• Positive hepatitis C or HIV serology, or positive hepatitis B serology not attributable to hepatitis B immunization.

• History of alcohol or drug abuse within 5 years prior to trial vaccination.

• Received experimental agent within 30 days prior to trial vaccination or expects to receive experimental agent (not including vaccines made available under an FDA emergency use authorization) anytime during the 6-month trial period.

• Female subjects that are breastfeeding or plan to breastfeed during the trial.

• Subjects who reside in a nursing home.

• Any condition that would in the opinion of the site investigator place the subject at unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.

Related Conditions & MeSH terms

• Respiratory Syncytial Virus Infections

Intervention

Biological:
• CPI-RSV-F Vaccine (BLB-201)
see arm/group description

Locations

Country	Name	City	State
United States	Cincinnati Children's Hospital Medical Center	Cincinnati	Ohio
United States	Coastal Carolina Research Center	North Charleston	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Blue Lake Biotechnology Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Spearman P, Jin H, Knopp K, Xiao P, Gingerich MC, Kidd J, Singh K, Tellier M, Radziewicz H, Wu S, McGregor M, Freda B, Wang Z, John SP, Villinger FJ, He B. Intranasal parainfluenza virus type 5 (PIV5)-vectored RSV vaccine is safe and immunogenic in health — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Solicited Adverse Events	Frequencies and grades of solicited local and systemic AEs during a 7-day period after dosing.	Day 1-8
Primary	Unsolicited Adverse Events	Frequencies and grades of unsolicited AEs during a 28-day period after dosing.	Day 1-29
Secondary	Serum IgG titers to RSV protein	Change in RSV specific IgG titers after the first dose of BLB-201.	Day 15, and Day 29
Secondary	Serious Adverse Events through trial completion	Frequencies of Serious Adverse Events (SAEs) categorized by vaccine relatedness from the first dose of BLB-201 through trial completion (approximately 6 months after dosing).	Day 1-181
Secondary	Serious adverse events, new-onset chronic medical conditions, and adverse events of special interest	Frequencies of Serious Adverse Events (SAEs) categorized by vaccine relatedness, new-onset chronic medical conditions (NOCMCs), and adverse events of special interest (MAAEs), from the first dose of BLB-201 through trial completion (approximately 6 months after dosing).	Day 1-181